Chiron Deal Offers Novartis Entry Into Vaccine Business
Novartis seeks to acquire remaining 57.8% of Chiron it does not already own with an all-cash bid of $4.5 bil.
Novartis seeks to acquire remaining 57.8% of Chiron it does not already own with an all-cash bid of $4.5 bil.